340 related articles for article (PubMed ID: 12717231)
1. Unexpected T-cell diversity in syngeneic graft-versus-host disease revealed by interaction with peptide-loaded soluble MHC class II molecules.
Hess AD; Thoburn CJ; Chen W; Bright AE
Transplantation; 2003 Apr; 75(8):1361-7. PubMed ID: 12717231
[TBL] [Abstract][Full Text] [Related]
2. Functional divergence of antigen-specific T-lymphocyte responses in syngeneic graft-versus-host disease.
Thoburn CJ; Miura Y; Bright EC; Hess AD
Biol Blood Marrow Transplant; 2004 Sep; 10(9):591-603. PubMed ID: 15319771
[TBL] [Abstract][Full Text] [Related]
3. Antigen-specific T-lymphocyte responses in acute and chronic syngeneic graft-versus-host disease.
Hess AD; Thoburn CJ; Miura Y; Bright EC
Transplant Proc; 2005; 37(1):53-6. PubMed ID: 15808545
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the pathogenic autoreactive T cells in cyclosporine-induced syngeneic graft-versus-host disease.
Chen W; Thoburn C; Hess AD
J Immunol; 1998 Dec; 161(12):7040-6. PubMed ID: 9862741
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the autoreactive T cell repertoire in cyclosporin-induced syngeneic graft-versus-host disease. A highly conserved repertoire mediates autoaggression.
Fischer AC; Ruvolo PP; Burt R; Horwitz LR; Bright EC; Hess JM; Beschorner WE; Hess AD
J Immunol; 1995 Apr; 154(8):3713-25. PubMed ID: 7706714
[TBL] [Abstract][Full Text] [Related]
6. Complexity of effector mechanisms in cyclosporine-induced syngeneic graft-versus-host disease.
Hess AD; Thoburn CJ; Chen W; Horwitz LR
Biol Blood Marrow Transplant; 2000; 6(1):13-24. PubMed ID: 10707995
[TBL] [Abstract][Full Text] [Related]
7. Characterization of peripheral autoregulatory mechanisms that prevent development of cyclosporin-induced syngeneic graft-versus-host disease.
Hess AD; Fischer AC; Horwitz L; Bright EC; Laulis MK
J Immunol; 1994 Jul; 153(1):400-11. PubMed ID: 8207251
[TBL] [Abstract][Full Text] [Related]
8. Functionally divergent T lymphocyte responses induced by modification of a self-peptide from a tumor-associated antigen.
Hess AD; Thoburn CJ; Miura Y; Bright EC
Clin Immunol; 2005 Mar; 114(3):307-19. PubMed ID: 15721842
[TBL] [Abstract][Full Text] [Related]
9. Immune tolerance to self-major histocompatibility complex class II antigens after bone marrow transplantation: role of regulatory T cells.
Hess AD; Thoburn CJ
Biol Blood Marrow Transplant; 2006 May; 12(5):518-29. PubMed ID: 16635787
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of the antigen presenting cell in rat autoimmune myocarditis: evidence of bone marrow derivation and non-requirement for MHC class I compatibility with pathogenic T cells.
Ratcliffe NR; Wegmann KW; Zhao RW; Hickey WF
J Autoimmun; 2000 Nov; 15(3):369-79. PubMed ID: 11040077
[TBL] [Abstract][Full Text] [Related]
11. Effector mechanisms in cyclosporine A-induced syngeneic graft-versus-host disease. Role of CD4+ and CD8+ T lymphocyte subsets.
Hess AD; Fischer AC; Beschorner WE
J Immunol; 1990 Jul; 145(2):526-33. PubMed ID: 1973185
[TBL] [Abstract][Full Text] [Related]
12. The N-terminal flanking region of the invariant chain peptide augments the immunogenicity of a cryptic "self" epitope from a tumor-associated antigen.
Hess AD; Thoburn C; Chen W; Miura Y; Van der Wall E
Clin Immunol; 2001 Oct; 101(1):67-76. PubMed ID: 11580228
[TBL] [Abstract][Full Text] [Related]
13. T cell recognition of flanking residues of murine invariant chain-derived CLIP peptide bound to MHC class II.
Naujokas MF; Southwood S; Mathies SJ; Appella E; Sette A; Miller J
Cell Immunol; 1998 Aug; 188(1):49-54. PubMed ID: 9743557
[TBL] [Abstract][Full Text] [Related]
14. Distinct TCRAV and TCRBV repertoire and CDR3 sequence of T lymphocytes clonally expanded in blood and GVHD lesions after human allogeneic bone marrow transplantation.
Hirokawa M; Matsutani T; Saitoh H; Ichikawa Y; Kawabata Y; Horiuchi T; Kitabayashi A; Yoshioka T; Tsuruta Y; Suzuki R; Miura AB; Sawada K
Bone Marrow Transplant; 2002 Dec; 30(12):915-23. PubMed ID: 12476285
[TBL] [Abstract][Full Text] [Related]
15. Th1 cytokines and NK cells participate in the development of murine syngeneic graft-versus-host disease.
Flanagan DL; Jennings CD; Bryson JS
J Immunol; 1999 Aug; 163(3):1170-7. PubMed ID: 10415011
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporine preferentially inhibits clonal deletion of CD8-positive T cells with an MHC class II restricted autoreactive T-cell receptor.
Severino ME; Laulis MK; Horwitz LR; Hess AD
Transplant Proc; 1993 Feb; 25(1 Pt 1):520-3. PubMed ID: 8438399
[No Abstract] [Full Text] [Related]
17. Promiscuous recognition of major histocompatibility complex class II determinants in cyclosporine-induced syngeneic graft-versus-host disease: specificity of cytolytic effector T cells.
Hess AD; Thoburn C; Horwitz L
Transplantation; 1998 Mar; 65(6):785-92. PubMed ID: 9539089
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporine-induced syngeneic graft-vs-host disease: prevention of autoaggression by treatment with monoclonal antibodies to T lymphocyte cell surface determinants and to MHC class II antigens.
Hess AD; Horwitz LR; Laulis MK; Fuchs E
Clin Immunol Immunopathol; 1993 Dec; 69(3):341-50. PubMed ID: 7694818
[TBL] [Abstract][Full Text] [Related]
19. Murine syngeneic graft-versus-host disease is responsive to broad-spectrum antibiotic therapy.
Brandon JA; Jennings CD; Kaplan AM; Bryson JS
J Immunol; 2011 Mar; 186(6):3726-34. PubMed ID: 21296982
[TBL] [Abstract][Full Text] [Related]
20. Specificity of effector mechanisms in syngeneic graft-vs-host disease: recognition of the MHC class II invariant chain peptide (CLIP).
Hess A; Thoburn C; Bright E; Horwitz L
Transplant Proc; 1997; 29(1-2):725-7. PubMed ID: 9123499
[No Abstract] [Full Text] [Related]
[Next] [New Search]
